Bill > HB469

This bill proposes to create a new section in Kentucky law that restricts the administration of human gene therapy products for infectious disease treatments. Specifically, the bill defines "human gene therapy products" as genetic materials or products that alter human genetic sequences, including nucleic acids, genetically modified microorganisms, genome editing tools, and genetically modified human cells. The legislation would prohibit healthcare providers from administering such products for infectious disease purposes, regardless of what they are called (immunization, vaccine, etc.). However, the bill includes important exceptions: human gene therapy products used to treat cancer or genetic disorders would be permitted. The provisions are set to expire on July 1, 2035, unless the Kentucky General Assembly chooses to extend them after reviewing safety data. The bill's stated intent is to protect Kentucky residents from potential adverse effects of experimental gene therapy products, effectively establishing a moratorium on gene therapy immunizations. An emergency clause is included, meaning the law would take effect immediately upon passage and approval by the Governor.

Health and Social Services

https://apps.legislature.ky.gov/record/25RS/hb469.html